T. Rowe Price Associates
OCUL icon

T. Rowe Price Associates’s Ocular Therapeutix OCUL Stock Holding History

T. Rowe Price Associates’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.9M Buy
7,623,533
+1,726,384
+29% +$15.6M 0.01% 769
2026
Q1 		$50M Buy
5,897,149
+5,725,625
+3,338% +$54.6M 0.01% 770
2025
Q4 		$2.08M Buy
171,524
+39,960
+30% +$485K ﹤0.01% 1733
2025
Q3 		$1.54M Buy
131,564
+5,198
+4% +$62.2K ﹤0.01% 1854
2025
Q2 		$1.17M Buy
126,366
+625
+0.5% +$4.89K ﹤0.01% 1917
2025
Q1 		$922K Sell
125,741
-513,223
-80% -$3.94M ﹤0.01% 2003
2024
Q4 		$5.46M Sell
638,964
-338,432
-35% -$3.3M ﹤0.01% 1267
2024
Q3 		$8.5M Sell
977,396
-133,058
-12% -$1.1M ﹤0.01% 1169
2024
Q2 		$7.6M Buy
1,110,454
+447,782
+68% +$2.76M ﹤0.01% 1149
2024
Q1 		$6.03M Buy
662,672
+609,328
+1,142% +$4.32M ﹤0.01% 1184
2023
Q4 		$238K Buy
53,344
+12,859
+32% +$38K ﹤0.01% 2474
2023
Q3 		$128K Buy
40,485
+1,846
+5% +$7.55K ﹤0.01% 2616
2023
Q2 		$200K Buy
38,639
+344
+0.9% +$2.05K ﹤0.01% 2534
2023
Q1 		$202K Sell
38,295
-3,566
-9% -$16.9K ﹤0.01% 2525
2022
Q4 		$118K Buy
41,861
+10,972
+36% +$36.3K ﹤0.01% 2682
2022
Q3 		$129K Buy
30,889
+4,981
+19% +$25.1K ﹤0.01% 2663
2022
Q2 		$104K Buy
25,908
+6,167
+31% +$23.3K ﹤0.01% 2750
2022
Q1 		$98K Buy
19,741
+6,481
+49% +$35.9K ﹤0.01% 2850
2021
Q4 		$92K Sell
13,260
-21,300
-62% -$165K ﹤0.01% 2887
2021
Q3 		$346K Sell
34,560
-100
-0.3% -$1.12K ﹤0.01% 2527
2021
Q2 		$491K Buy
34,660
+1,759
+5% +$26.7K ﹤0.01% 2400
2021
Q1 		$540K Buy
32,901
+6,973
+27% +$134K ﹤0.01% 2332
2020
Q4 		$537K Buy
+25,928
New +$385K ﹤0.01% 2212

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's OCUL Position: Q2 2026 in Review

T. Rowe Price Associates increased its Ocular Therapeutix (OCUL) stake by 29% in Q2 2026, buying an estimated $15.6M and bringing the position to 7,623,533 shares worth $74.9M. The position accounts for 0.01% of the portfolio, ranked #769.

T. Rowe Price Associates first reported a position in OCUL in Q4 2020 and has held it in 23 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • T. Rowe Price Associates held 7,623,533 shares of Ocular Therapeutix worth $74.9M as of Q2 2026.
  • T. Rowe Price Associates bought 1,726,384 Ocular Therapeutix shares in Q2 2026, an estimated $15.6M.
  • Ocular Therapeutix made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #769 holding.
  • T. Rowe Price Associates first reported a position in Ocular Therapeutix in Q4 2020 and has held it in 23 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.